245 related articles for article (PubMed ID: 11194468)
21. Therapeutic effects of tolvaptan, a potent, selective nonpeptide vasopressin V2 receptor antagonist, in rats with acute and chronic severe hyponatremia.
Miyazaki T; Yamamura Y; Onogawa T; Nakamura S; Kinoshita S; Nakayama S; Fujiki H; Mori T
Endocrinology; 2005 Jul; 146(7):3037-43. PubMed ID: 15831573
[TBL] [Abstract][Full Text] [Related]
22. Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands.
Serradeil-Le Gal C; Wagnon J; Valette G; Garcia G; Pascal M; Maffrand JP; Le Fur G
Prog Brain Res; 2002; 139():197-210. PubMed ID: 12436936
[TBL] [Abstract][Full Text] [Related]
23. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.
Yamamura Y; Nakamura S; Itoh S; Hirano T; Onogawa T; Yamashita T; Yamada Y; Tsujimae K; Aoyama M; Kotosai K; Ogawa H; Yamashita H; Kondo K; Tominaga M; Tsujimoto G; Mori T
J Pharmacol Exp Ther; 1998 Dec; 287(3):860-7. PubMed ID: 9864265
[TBL] [Abstract][Full Text] [Related]
24. Tolvaptan is successful in treating inappropriate antidiuretic hormone secretion in infants.
Marx-Berger D; Milford DV; Bandhakavi M; Van't Hoff W; Kleta R; Dattani M; Bockenhauer D
Acta Paediatr; 2016 Jul; 105(7):e334-7. PubMed ID: 27028950
[TBL] [Abstract][Full Text] [Related]
25. Inappropriate secretion of antidiuretic hormone in a dog.
Breitschwerdt EB; Root CR
J Am Vet Med Assoc; 1979 Jul; 175(2):181-6. PubMed ID: 500439
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic potential of vasopressin receptor antagonists.
Ali F; Guglin M; Vaitkevicius P; Ghali JK
Drugs; 2007; 67(6):847-58. PubMed ID: 17428103
[TBL] [Abstract][Full Text] [Related]
27. Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist.
Soupart A; Gross P; Legros JJ; Alföldi S; Annane D; Heshmati HM; Decaux G
Clin J Am Soc Nephrol; 2006 Nov; 1(6):1154-60. PubMed ID: 17699341
[TBL] [Abstract][Full Text] [Related]
28. Inappropriate vasopressin secretion in two dogs.
Rijnberk A; Biewenga WJ; Mol JA
Acta Endocrinol (Copenh); 1988 Jan; 117(1):59-64. PubMed ID: 3381626
[TBL] [Abstract][Full Text] [Related]
29. Pharmacological profile of YM087, a novel nonpeptide dual vasopressin V1A and V2 receptor antagonist, in dogs.
Yatsu T; Tomura Y; Tahara A; Wada K; Tsukada J; Uchida W; Tanaka A; Takenaka T
Eur J Pharmacol; 1997 Feb; 321(2):225-30. PubMed ID: 9063692
[TBL] [Abstract][Full Text] [Related]
30. [Diagnostics and new treatment methods of syndrome of inappropriate antidiuretic hormone secretion (SIADH)].
Trolle C; Rittig S; Frøkjær J; Jørgensen JO
Ugeskr Laeger; 2012 Apr; 174(15):1019-22. PubMed ID: 22487409
[TBL] [Abstract][Full Text] [Related]
31. Long-term treatment of patients with inappropriate secretion of antidiuretic hormone by the vasopressin receptor antagonist conivaptan, urea, or furosemide.
Decaux G
Am J Med; 2001 May; 110(7):582-4. PubMed ID: 11343672
[No Abstract] [Full Text] [Related]
32. Atrial natriuretic peptide in patients with the syndrome of inappropriate antidiuretic hormone secretion and with diabetes insipidus.
Kamoi K; Ebe T; Kobayashi O; Ishida M; Sato F; Arai O; Tamura T; Takagi A; Yamada A; Ishibashi M
J Clin Endocrinol Metab; 1990 May; 70(5):1385-90. PubMed ID: 2139879
[TBL] [Abstract][Full Text] [Related]
33. Effects of long-term oral treatment with selective vasopressin V2 receptor antagonist (OPC-31260) on adriamycin-induced heart failure in rats.
Takeuchi M; Lee JD; Shimizu H; Ueda T
Int J Cardiol; 2006 Apr; 108(2):231-6. PubMed ID: 16002161
[TBL] [Abstract][Full Text] [Related]
34. Syndrome of inappropriate antidiuretic hormone secretion concurrent with liver disease in a dog.
Kang MH; Park HM
J Vet Med Sci; 2012 May; 74(5):645-9. PubMed ID: 22185769
[TBL] [Abstract][Full Text] [Related]
35. Effect of long-term treatment with selective vasopressin V1 and V2 receptor antagonist on the development of heart failure in rats.
Nishikimi T; Kawano Y; Saito Y; Matsuoka H
J Cardiovasc Pharmacol; 1996 Feb; 27(2):275-82. PubMed ID: 8720428
[TBL] [Abstract][Full Text] [Related]
36. Effects of tolvaptan on systemic and renal hemodynamic function in dogs with congestive heart failure.
Onogawa T; Sakamoto Y; Nakamura S; Nakayama S; Fujiki H; Yamamura Y
Cardiovasc Drugs Ther; 2011 Dec; 25 Suppl 1():S67-76. PubMed ID: 22120095
[TBL] [Abstract][Full Text] [Related]
37. Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH).
Gassanov N; Semmo N; Semmo M; Nia AM; Fuhr U; Er F
Eur J Clin Pharmacol; 2011 Apr; 67(4):333-346. PubMed ID: 21327910
[TBL] [Abstract][Full Text] [Related]
38. Tolvaptan for SIADH in Myelodysplastic Syndrome with Blast Crisis.
Mali P; Muduganti SR; Mujibur R; Murali N
WMJ; 2015 Apr; 114(2):66-8. PubMed ID: 26756059
[TBL] [Abstract][Full Text] [Related]
39. [Lower doses of tolvaptan in hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion].
Sánchez Sobrino P; Fernández Catalina P; Lorenzo Solar M; Rego Iraeta A
Med Clin (Barc); 2015 Aug; 145(3):138-9. PubMed ID: 25543222
[No Abstract] [Full Text] [Related]
40. Biological half-life and organ distribution of [3H]8-arginine vasopressin following administration of vasopressin receptor antagonist OPC-31260.
Molnár AH; Varga C; Janáky T; Tóth G; Tóth G; Farkas J; László F; László FA
Regul Pept; 2007 Jun; 141(1-3):12-8. PubMed ID: 17258819
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
